Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1882-1884

  Ganjoo, Kristen N ^a   Demetri, George D ^b   Jacobs, Charlotte ^a   Patel, Shreyaskumar ^c  

^a STANFORD CANCER INSTITUTE   (United States)

^b Harvard Center for Cancer Biology   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DACARBAZINE; ETOPOSIDE; GEMCITABINE; IDARUBICIN; IMATINIB; MITOXANTRONE; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW BIOPSY; CANCER SURGERY; CASE REPORT; CYTOGENETICS; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; LEUKEMIA RELAPSE; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ACUTE DISEASE; AGED; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 71049179371     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903242610     Document Type: Letter

References (13)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
2. Spandaro P, Ingemi M, Pitini V, Arrigo C, Soto Parra H. Myelodysplastic syndromes developing after imatinib therapy for GIST. J Clin Oncol 2009;27:543s.
3. Pitini V, Arrigo C, Sauta MG, Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res 2009;33:e143-e144.
4. Fiedler W, Serve H, Dohner H, et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
5. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation of FLT3 respond to small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
6. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-3676.
7. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of FLT3 inhibitor lesraurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108: 3262-3270.
8. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical research council AML 10 and 12 trials. Blood 2001;98:1752-1759.
9. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J Clin Oncol 2006;24:3904-3911. (Pubitemid 46630738)
10. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2013.
11. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of cancer therapeutic agent Imatinib mesylate. Nat Med 2006;12:908-916.
12. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiotoxicity of sunitinib and sorafenib in patients with renal cell carcinoma. J Clin Oncol 2008;26:5204-5212.
13. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. JNCI 2007;99:81-83.